Cargando…

Novel Tetrazole-Based Antimicrobial Agents Targeting Clinical Bacteria Strains: Exploring the Inhibition of Staphylococcus aureus DNA Topoisomerase IV and Gyrase

Eleven novel imide-tetrazoles were synthesized. In the initial stage of research, in silico structure-based pharmacological prediction was conducted. All compounds were screened for antimicrobial activity using standard and clinical strains. Within the studied group, compounds 1–3 were recognized as...

Descripción completa

Detalles Bibliográficos
Autores principales: Roszkowski, Piotr, Szymańska-Majchrzak, Jolanta, Koliński, Michał, Kmiecik, Sebastian, Wrzosek, Małgorzata, Struga, Marta, Szulczyk, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745314/
https://www.ncbi.nlm.nih.gov/pubmed/35008805
http://dx.doi.org/10.3390/ijms23010378
_version_ 1784630315478679552
author Roszkowski, Piotr
Szymańska-Majchrzak, Jolanta
Koliński, Michał
Kmiecik, Sebastian
Wrzosek, Małgorzata
Struga, Marta
Szulczyk, Daniel
author_facet Roszkowski, Piotr
Szymańska-Majchrzak, Jolanta
Koliński, Michał
Kmiecik, Sebastian
Wrzosek, Małgorzata
Struga, Marta
Szulczyk, Daniel
author_sort Roszkowski, Piotr
collection PubMed
description Eleven novel imide-tetrazoles were synthesized. In the initial stage of research, in silico structure-based pharmacological prediction was conducted. All compounds were screened for antimicrobial activity using standard and clinical strains. Within the studied group, compounds 1–3 were recognized as leading structures with the most promising results in antimicrobial studies. Minimal inhibitory concentration values for compounds 1, 2, 3 were within the range of 0.8–3.2 μg/mL for standard and clinical Gram-positive and Gram-negative bacterial strains, showing in some cases higher activity than the reference Ciprofloxacin. Additionally, all three inhibited the growth of all clinical Staphylococci panels: Staphylococcus aureus (T5592; T5591) and Staphylococcus epidermidis (5253; 4243) with MIC values of 0.8 μg/mL. Selected compounds were examined in topoisomerase IV decatenation assay and DNA gyrase supercoiling assay, followed by suitable molecular docking studies to explore the possible binding modes. In summary, the presented transition from substrate imide-thioureas to imide-tetrazole derivatives resulted in significant increase of antimicrobial properties. The compounds 1–3 proposed here provide a promising basis for further exploration towards novel antimicrobial drug candidates.
format Online
Article
Text
id pubmed-8745314
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87453142022-01-11 Novel Tetrazole-Based Antimicrobial Agents Targeting Clinical Bacteria Strains: Exploring the Inhibition of Staphylococcus aureus DNA Topoisomerase IV and Gyrase Roszkowski, Piotr Szymańska-Majchrzak, Jolanta Koliński, Michał Kmiecik, Sebastian Wrzosek, Małgorzata Struga, Marta Szulczyk, Daniel Int J Mol Sci Article Eleven novel imide-tetrazoles were synthesized. In the initial stage of research, in silico structure-based pharmacological prediction was conducted. All compounds were screened for antimicrobial activity using standard and clinical strains. Within the studied group, compounds 1–3 were recognized as leading structures with the most promising results in antimicrobial studies. Minimal inhibitory concentration values for compounds 1, 2, 3 were within the range of 0.8–3.2 μg/mL for standard and clinical Gram-positive and Gram-negative bacterial strains, showing in some cases higher activity than the reference Ciprofloxacin. Additionally, all three inhibited the growth of all clinical Staphylococci panels: Staphylococcus aureus (T5592; T5591) and Staphylococcus epidermidis (5253; 4243) with MIC values of 0.8 μg/mL. Selected compounds were examined in topoisomerase IV decatenation assay and DNA gyrase supercoiling assay, followed by suitable molecular docking studies to explore the possible binding modes. In summary, the presented transition from substrate imide-thioureas to imide-tetrazole derivatives resulted in significant increase of antimicrobial properties. The compounds 1–3 proposed here provide a promising basis for further exploration towards novel antimicrobial drug candidates. MDPI 2021-12-29 /pmc/articles/PMC8745314/ /pubmed/35008805 http://dx.doi.org/10.3390/ijms23010378 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Roszkowski, Piotr
Szymańska-Majchrzak, Jolanta
Koliński, Michał
Kmiecik, Sebastian
Wrzosek, Małgorzata
Struga, Marta
Szulczyk, Daniel
Novel Tetrazole-Based Antimicrobial Agents Targeting Clinical Bacteria Strains: Exploring the Inhibition of Staphylococcus aureus DNA Topoisomerase IV and Gyrase
title Novel Tetrazole-Based Antimicrobial Agents Targeting Clinical Bacteria Strains: Exploring the Inhibition of Staphylococcus aureus DNA Topoisomerase IV and Gyrase
title_full Novel Tetrazole-Based Antimicrobial Agents Targeting Clinical Bacteria Strains: Exploring the Inhibition of Staphylococcus aureus DNA Topoisomerase IV and Gyrase
title_fullStr Novel Tetrazole-Based Antimicrobial Agents Targeting Clinical Bacteria Strains: Exploring the Inhibition of Staphylococcus aureus DNA Topoisomerase IV and Gyrase
title_full_unstemmed Novel Tetrazole-Based Antimicrobial Agents Targeting Clinical Bacteria Strains: Exploring the Inhibition of Staphylococcus aureus DNA Topoisomerase IV and Gyrase
title_short Novel Tetrazole-Based Antimicrobial Agents Targeting Clinical Bacteria Strains: Exploring the Inhibition of Staphylococcus aureus DNA Topoisomerase IV and Gyrase
title_sort novel tetrazole-based antimicrobial agents targeting clinical bacteria strains: exploring the inhibition of staphylococcus aureus dna topoisomerase iv and gyrase
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745314/
https://www.ncbi.nlm.nih.gov/pubmed/35008805
http://dx.doi.org/10.3390/ijms23010378
work_keys_str_mv AT roszkowskipiotr noveltetrazolebasedantimicrobialagentstargetingclinicalbacteriastrainsexploringtheinhibitionofstaphylococcusaureusdnatopoisomeraseivandgyrase
AT szymanskamajchrzakjolanta noveltetrazolebasedantimicrobialagentstargetingclinicalbacteriastrainsexploringtheinhibitionofstaphylococcusaureusdnatopoisomeraseivandgyrase
AT kolinskimichał noveltetrazolebasedantimicrobialagentstargetingclinicalbacteriastrainsexploringtheinhibitionofstaphylococcusaureusdnatopoisomeraseivandgyrase
AT kmieciksebastian noveltetrazolebasedantimicrobialagentstargetingclinicalbacteriastrainsexploringtheinhibitionofstaphylococcusaureusdnatopoisomeraseivandgyrase
AT wrzosekmałgorzata noveltetrazolebasedantimicrobialagentstargetingclinicalbacteriastrainsexploringtheinhibitionofstaphylococcusaureusdnatopoisomeraseivandgyrase
AT strugamarta noveltetrazolebasedantimicrobialagentstargetingclinicalbacteriastrainsexploringtheinhibitionofstaphylococcusaureusdnatopoisomeraseivandgyrase
AT szulczykdaniel noveltetrazolebasedantimicrobialagentstargetingclinicalbacteriastrainsexploringtheinhibitionofstaphylococcusaureusdnatopoisomeraseivandgyrase